MAIA presents Phase 2 THIO-101 poster at WCLC showing PFS improvement in advanced NSCLC

MAIA Biotechnology, Inc.

Poster titled 'Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS' presented at 2025 WCLC on Sept 7, 2025.
Data from Phase 2 THIO-101 trial evaluating THIO + cemiplimab in advanced NSCLC patients who failed ≥2 prior therapies.
Specific efficacy numbers (e.g., median PFS, response rates) not disclosed in the filing; poster available on company website Sept 8.
No safety or additional endpoints described in this filing.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.